{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/heart-failure-chronic/diagnosis/how-to-manage-suspected/","result":{"pageContext":{"chapter":{"id":"e6498250-f313-5ea2-a1e8-2d0342823c39","slug":"how-to-manage-suspected","fullItemName":"How to manage suspected","depth":2,"htmlHeader":"<!-- begin field d87ccf56-07a8-4171-b7b8-cde181769d28 --><h2>How should I manage a person with suspected heart failure?</h2><!-- end field d87ccf56-07a8-4171-b7b8-cde181769d28 -->","summary":"","htmlStringContent":"<!-- begin item 1a17235f-e448-45e0-b6f6-b8ba12b152d3 --><!-- begin field 79d44bf7-311a-4ea3-98b5-22af826bf599 --><ul><li>Review the person's medication and if appropriate reduce or stop any drugs that may cause or worsen heart failure.</li><li>If symptoms are sufficiently severe, start a loop diuretic such as:<ul><li>Furosemide 20–40 mg daily.</li><li>Bumetanide 0.5–1.0 mg daily.</li><li>Torasemide 5–10 mg daily.</li></ul></li><li>If higher doses are required to relieve the person's symptoms, check adherence to treatment, check for <span class=\"Cross-reference\"><a class=\"topic-reference internal-reference\" href=\"/topics/heart-failure-chronic/diagnosis/what-else-could-it-be/\">alternative causes</a></span>, and seek specialist advice or consider admission (based on clinical judgement).</li><li>Seek specialist advice for pregnant women before initiating any drug treatments.</li></ul><!-- end field 79d44bf7-311a-4ea3-98b5-22af826bf599 --><!-- end item 1a17235f-e448-45e0-b6f6-b8ba12b152d3 -->","topic":{"id":"3a35207f-30ea-5eca-bfcf-dff091a73359","topicId":"fdc42e20-2c4b-45ed-9093-6c2d4bde6e4d","topicName":"Heart failure - chronic","slug":"heart-failure-chronic","lastRevised":"Last revised in January 2017","chapters":[{"id":"77c928c1-46d0-58c1-ba79-6015f89bc48a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f0aa9151-9d10-566e-85ec-6ccefed25f20","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c036596d-f29d-5486-822a-b46af76451d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd5e8a95-3e97-5ec2-98ae-5a10c2373213","slug":"changes","fullItemName":"Changes"},{"id":"4c4375f1-a348-5b99-b895-f04a15c64791","slug":"update","fullItemName":"Update"}]},{"id":"7472c037-35d4-5fd2-bba6-dfd891ade816","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cde936d1-3945-5bc6-8c22-9106d78cf77c","slug":"goals","fullItemName":"Goals"},{"id":"bfa0b8d3-fac0-500e-a762-f719dc619f1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5d2cf55e-1ae2-5000-9c94-e9c86d26a824","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c8203a8a-fc22-5378-b33b-34ddf818dea5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4b5e4f72-1a3e-531c-be82-a1919603c934","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c206f1b2-7616-587d-b3bf-b65ba5b5adb4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ab1d2b81-1f2b-55e5-abf0-c14e4ae4a78d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"cb83ac3c-e97e-5cab-acca-5abebc7bd6b1","slug":"definition","fullItemName":"Definition"},{"id":"66c995b7-504c-5510-9e77-1a9b27ee7dca","slug":"causes","fullItemName":"Causes"},{"id":"88dbdf7b-53b7-5952-97b9-2312c0a2ce63","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0b16521-d808-5dfd-89dc-64fc6ae7f6ce","slug":"prognosis","fullItemName":"Prognosis"},{"id":"262fb896-526d-594f-8142-98c291781249","slug":"complications","fullItemName":"Complications"}]},{"id":"72804751-fb0c-5a96-85b5-982feb950f16","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8b798e41-3fbe-5027-9365-da41e1c98e93","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"e6498250-f313-5ea2-a1e8-2d0342823c39","slug":"how-to-manage-suspected","fullItemName":"How to manage suspected"},{"id":"74e553b4-7cb8-52a6-a573-8715f63a2ba8","slug":"how-to-assess","fullItemName":"How to assess"},{"id":"53bf7ae0-a1d0-5fae-9d3b-57cbc6f03bb8","slug":"what-else-could-it-be","fullItemName":"What else could it be"}]},{"id":"38c5edc8-6b4a-5e71-bb70-cf0a09389ae0","fullItemName":"Management","slug":"management","subChapters":[{"id":"97a0eca4-a290-588b-a16a-bc95b93cd893","slug":"confirmed-heart-failure-with-reduced-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with reduced ejection fraction"},{"id":"34ff8094-815a-55b7-9edd-49f3ac636471","slug":"confirmed-heart-failure-with-preserved-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with preserved ejection fraction"},{"id":"28fde475-ef24-59d3-9171-a8d59a3fb149","slug":"end-stage-heart-failure","fullItemName":"Scenario: End-stage heart failure"},{"id":"c587255a-a47e-57a1-bc4d-967753c38d11","slug":"information-advice-follow-up-referral","fullItemName":"Scenario: Information and advice, follow-up, and referral"}]},{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8fd96acc-3fa6-528b-9351-49db836228b1","slug":"managing-aiiras","fullItemName":"Managing AIIRAs"},{"id":"06c9d276-e5ea-5a0b-9ff4-343f10034763","slug":"managing-ace-inhibitors","fullItemName":"Managing ACE-inhibitors"},{"id":"df53e9a8-07f8-5d37-94cf-78e99d4c8216","slug":"managing-beta-blockers","fullItemName":"Managing beta-blockers"},{"id":"faad170c-d1ee-59ad-9847-f7afdda6d9b9","slug":"managing-diuretics","fullItemName":"Managing diuretics"},{"id":"a3ea6beb-7ee3-586c-9985-47c20d804195","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"7b9c5d56-39f1-53df-b1f9-2dcc5bbb498a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"df3b6e0c-ca5a-59eb-93e6-4b4370389ed2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7a756ff1-7152-5bdd-92ca-7f9e67351dd9","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f5e1707e-f2a9-54e0-92fa-71beb41e38af","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"691681cc-720f-5242-9fb3-3040860027e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7f39ec24-cb87-5fba-ae6b-6fb2d9538859","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4afe2b30-f837-53a3-88df-7b1913a54081","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d4dace55-ef1c-5675-bdbe-180512d549fa","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"72804751-fb0c-5a96-85b5-982feb950f16","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"928c1bfd-ccc6-53ec-ad12-a5847e31804e","slug":"basis-for-recommendation-458","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field dceb6623-a714-4c65-813d-e0bd667d9191 --><h3>Basis for recommendation</h3><!-- end field dceb6623-a714-4c65-813d-e0bd667d9191 -->","summary":null,"htmlStringContent":"<!-- begin item 45845913-a36c-4e9d-86b0-12a6ee490b35 --><!-- begin field 95f11187-2dc7-48ba-91ac-4342082cdd53 --><p>These recommendations are based on guidelines from the Scottish Intercollegiate Guidelines Network (SIGN) <em>Management of chronic heart failure</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>], the National Institute for Health and Clinical Excellence (NICE) <em>Chronic heart failure national guidelines for diagnosis and management in primary and secondary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>], on a previous and current guideline published by the European Society of Cardiology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>], and the expert opinion of previous reviewers of this CKS topic.<br><strong>Reviewing medication</strong></p><ul><li>This recommendation is based on expert opinion in a narrative review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Williams and Oakeshott, 2014a</a>].</li></ul><p><strong>Starting loop diuretics</strong></p><ul><li>The recommendation to start a loop diuretic to relieve symptoms is extrapolated from the guidelines from SIGN [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>], NICE [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>], and the European Society of Cardiology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>], and is recommended in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">Williams and Oakeshott, 2014a</a>].</li><li>CKS recommends that specialist advice should be sought if daily doses higher than furosemide 40 mg (or equivalent) are needed because:<ul><li>There may be a need to consider an alternative diagnosis (particularly if the person is responding poorly to a diuretic).</li><li>High doses of loop diuretic may cause profound hypotension if an angiotensin-converting enzyme (ACE) inhibitor needs to be started, as symptomatic first-dose hypotension is more likely to occur in people taking diuretics, particularly if the dose of diuretic is high [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">BNF 72, 2016</a>].</li><li>High doses of diuretic may result in hypokalaemia and other electrolyte disturbances, and acute kidney injury and chronic kidney disease have been reported [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>].</li><li>The expert opinion of previous reviewers of this CKS topic agreed that the daily dose of a loop diuretic should not exceed furosemide 40 mg (or equivalent) for the management of suspected heart failure, unless specialist advice is obtained.</li></ul></li></ul><p><strong>Checking adherence to treatment, alternative causes, and seeking specialist advice or considering admission</strong></p><ul><li>This recommendation is pragmatic and based on what CKS considers to be good clinical practice.</li></ul><p><strong>Seeking specialist advice for pregnant women</strong></p><ul><li>This recommendation is based on expert opinion that a high index of suspicion is needed to avoid late diagnosis of peripartum cardiomyopathy in the guidelines from the European Society of Cardiology <em>Guidelines on the management of cardiovascular diseases during pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2011</a>], and information that a risk assessment should be carried out early in pregnancy by a specialist obstetrician, cardiologist, and anaesthetist in the guideline from the Royal College of Obstetricians and Gynaecologists <em>Cardiac disease and pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">RCOG, 2011</a>]. Additionally, some medications used for treatment of heart failure (such as ACE-inhibitors and angiotensin-II receptor antagonists) are contraindicated in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">European Society of Cardiology, 2012</a>].</li></ul><!-- end field 95f11187-2dc7-48ba-91ac-4342082cdd53 --><!-- end item 45845913-a36c-4e9d-86b0-12a6ee490b35 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}